1. HBW Insight
  2. >>Wellness
  3. >>Policy & Regulation
  4. >>Regulation

FDA Using Ion Mobility Spectrometers In 4 IMFs, Plans Use In 4 More

 
• By Malcolm Spicer

Across all 9 IMF facilities in FY 2019, FDA screened around 25,200 parcels containing more than 41,000 products, detained more than 38,000 including 1,801 identified as supplements and expects to destroy more than 17,000.

Stop barrier

The Food and Drug Administration has extended use of ion mobility spectrometer portable screening devices to four of the nine US international mail facilities and plans to deploy the technology in four other IMFs.

Representatives from acting Commissioner Normal "Ned" Sharpless' office provided an update on the FDA's use of the devices following Sharpless'...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Latest OTC Eye Drop Production Problem In US Prompts Firm To Close Doors After Recalls

 
• By Malcolm Spicer

BRS Analytical Services in St. Louis recalled more than 75,000 cases of redness and lubricating eye drops and committed “to permanently cease production of all drugs.”

‘You Are Very Regulated’: Consumer Health And Beauty Industries’ Attention Needed In California

 
• By Malcolm Spicer

Regulations likely holding consumer product firms’ attention include the Plastic Pollution Prevention and Packaging Producer Responsibility Act, SB 54, scheduled to become effective by 2027. “Easily the most significant, extended producer responsibility law ever to pass in the world,” says lobbyist

US FDA Independence Questioned At CDC Oversight Hearing

 
• By Michael McCaughan

A Senate committee is investigating leadership changes at the US Centers for Disease Control and Prevention. While the primary focus is vaccine policy, the first hearing suggested the probe could raise questions about FDA independence.

NPA On Clock To Continue Challenge To FDA ‘Drug Preclusion’ Policy For Dietary Ingredients

 
• By Malcolm Spicer

FDA rejects NPAs arguments for clarity on when it recognizes start of investigational new drug programs and what constitutes “substantial clinical investigations” for an IND. Clock starts after FDA met twice-extended deadline to provide answers to NPA’s questions in a 2023 petition.

More from Policy & Regulation

Limiting Presidential Power Could Swing On Challenges To Trump’s Claimed Tariff Authority

 
• By Malcolm Spicer

Speakers at recent Council for Responsible Nutrition conference noted Trump using executive office authorities to extent no other president has while discussing impact of his tariff-driven trade policies on US industries and complaints challenging his tariff orders the Supreme Court will consider.

CDER Director Sows Doubt US FDA Will Move Away From UV Filter Animal Tests

 
• By Lauren Nardella

Center for Drug Evaluation and Research Director George Tidmarsh emphasizes the reduction, but not necessarily the elimination, of animal tests for UV filters in an FDA Voices post, raising questions about the agency’s intentions.

‘You Are Very Regulated’: Consumer Health And Beauty Industries’ Attention Needed In California

 
• By Malcolm Spicer

Regulations likely holding consumer product firms’ attention include the Plastic Pollution Prevention and Packaging Producer Responsibility Act, SB 54, scheduled to become effective by 2027. “Easily the most significant, extended producer responsibility law ever to pass in the world,” says lobbyist